Register for email alerts and news feeds:
This journal | BMJ Group
rss
Heart 2005;91:707-709; doi:10.1136/hrt.2004.057190
Copyright © 2005 BMJ Publishing Group Ltd & British Cardiovascular Society
Heart 2005;91:707-709
© 2005 by BMJ Publishing Group & British Cardiac Society

EDITORIAL

Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure?

W Doehner, S D Anker*

Division of Applied Cachexia Research, Department of Cardiology, Charité Medical School, Campus Virchow-Klinikum, Berlin, Germany

Correspondence to:
Correspondence to:
Wolfram Doehner
MD, PhD, Division of Applied Cachexia Research, Department of Cardiology, Charité, Campus Virchow-Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany ; wolfram.doehner{at}charite.de

ABSTRACT

A substantial body of evidence has accumulated to suggest a role for the xanthine oxidase metabolic pathway in the pathophysiology of chronic heart failure and other cardiovascular diseases

Abbreviations: BNP, brain natriuretic peptide; CHF, chronic heart failure; NO, nitric oxide; XO, xanthine oxidase

Keywords: allopurinol; heart failure; xanthine oxidoreductase


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Hadizadeh, M., Keyhani, E., Keyhani, J., Khodadadi, C. (2009). Functional and structural alterations induced by copper in xanthine oxidase. Acta Biochim Biophys Sin 41: 603-617 [Abstract] [Full Text]  
  • Xiao, J., She, Q., Wang, Y., Luo, K., Yin, Y., Hu, R., Huang, K. (2009). Effect of allopurinol on cardiomyocyte apoptosis in rats after myocardial infarction. Eur J Heart Fail 11: 20-27 [Abstract] [Full Text]  
  • Doehner, W., Springer, J., Anker, S. D., Landmesser, U., Struthers, A. D. (2008). Uric acid in chronic heart failure--current pathophysiological concepts. Eur J Heart Fail 10: 1269-1270 [Full Text]  
  • Boueiz, A., Damarla, M., Hassoun, P. M. (2008). Xanthine oxidoreductase in respiratory and cardiovascular disorders. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L830-L840 [Abstract] [Full Text]  
  • Cleland, J. G.F., Coletta, A. P., Clark, A. L. (2006). Clinical trials update from the Heart Failure Society of America meeting: FIX-CHF-4, selective cardiac myosin activator and OPT-CHF. Eur J Heart Fail 8: 764-766 [Abstract] [Full Text]  
  • Pacher, P., Nivorozhkin, A., Szabo, C. (2006). Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol.. Pharmacol. Rev. 58: 87-114 [Abstract] [Full Text]  

This Article

Services
Citing Articles
Google Scholar
PubMed
Topic Collections
Bookmark with

Register for free content

The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Show me all >>